Pharmacogenetic analysis of INT 0144 trial: Association of polymorphisms with survival and toxicity in rectal cancer patients treated with 5-FU and radiation

Pierre Bohanes, Cathryn J. Rankin, Charles D. Blanke, Thomas Winder, Cornelia M. Ulrich, Stephen R. Smalley, Tyvin A. Rich, James A. Martensen, Al B.Benson Iii, Robert J. Mayer, Christine M. Cripps, Kathleen Danenberg, Karen W. Makar, Wu Zhang, Jacqueline K. Benedetti, Heinz Josef Lenz

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Purpose: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy. Experimental Design: DNA from 746 stage II/III rectal patients enrolled in the Southwest Oncology Group (SWOG) S9304 phase III trial was analyzed. Genomic DNA was extracted from formalin-fixed, paraffin-embedded (FFPE) tumor tissue. The polymorphisms were analyzed using direct DNA-sequencing or polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Results: GSTP1-Ile105Val (rs1695) was significantly associated with DFS and OS and its effect did not vary by treatment arm. The five-year DFS and OS were 53% and 58%, respectively, for G/G, 66% and 72% for G/A, and 57% and 66% for A/A patients. In arm 2, IL8-251A/A genotype (rs4073) was associated with a lower risk of toxicities (P = 0.04). The VEGFR2 H472Q Q/Q genotype (rs1870377) was associated with a higher risk of grade 3-5 proximal upper gastrointestinal tract (PUGIT) mucositis (P = 0.04) in arm 2. However, in arm 1, this genotype was associated with a lower risk of PUGIT mucositis (P = 0.004). Conclusion: rs1695 may be prognostic in patients with rectal cancer treated with adjuvant CRT. rs4073 and rs1870377 may exhibit different associations with toxicity, according to the 5-FU schedule.

Original languageEnglish (US)
Pages (from-to)1583-1590
Number of pages8
JournalClinical Cancer Research
Volume21
Issue number7
DOIs
StatePublished - Apr 1 2015

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Pharmacogenetic analysis of INT 0144 trial: Association of polymorphisms with survival and toxicity in rectal cancer patients treated with 5-FU and radiation'. Together they form a unique fingerprint.

  • Cite this

    Bohanes, P., Rankin, C. J., Blanke, C. D., Winder, T., Ulrich, C. M., Smalley, S. R., Rich, T. A., Martensen, J. A., Iii, A. B. B., Mayer, R. J., Cripps, C. M., Danenberg, K., Makar, K. W., Zhang, W., Benedetti, J. K., & Lenz, H. J. (2015). Pharmacogenetic analysis of INT 0144 trial: Association of polymorphisms with survival and toxicity in rectal cancer patients treated with 5-FU and radiation. Clinical Cancer Research, 21(7), 1583-1590. https://doi.org/10.1158/1078-0432.CCR-14-0857